Emerging Advances in Rapid Diagnostics of Respiratory Infections

David R. Murdoch, MD, MSc, DTM&H, FRACP, FRCPAa,b,*
Lance C. Jennings, PhD, FRCPPatha,b, Niranjan Bhat, MDc
Trevor P. Anderson, MSCb

Diagnostic laboratories play a central role in the recognition of new and emerging infections. The identification of the severe acute respiratory syndrome (SARS) coronavirus in 2003 highlighted how modern diagnostic tools and collaboration between clinicians, public health professionals, and laboratorians can lead to the rapid characterization of a new respiratory pathogen.1 Similarly, the development and rapid dissemination of a polymerase chain reaction (PCR) method to detect the novel H1N1 influenza A strain by the US Centers for Disease Control and Prevention in 2009, relied on the most recent diagnostic technology and played an important role in the response to the latest influenza pandemic.2 These events remind us of how much recent developments in diagnostics have improved our ability to identify respiratory
viruses. For nonviral respiratory pathogens, developments in laboratory technology have been less profound in general, but have still led to modest improvements in the diagnostic capability.

For the diagnostic microbiology laboratory, the routine evaluation of patients with suspected respiratory infections continues to rely on methods that have been used for a long time: microscopy and culture of respiratory tract specimens, blood cultures, detection of antigens in urine and upper respiratory specimens, and serology. Recent advances in pneumonia diagnostics have mostly occurred in the areas of antigen and nucleic acid detection. Despite these technological advances, there remain several major challenges that hinder the search for the causes of respiratory infections, particularly for pneumonia. These challenges include difficulty collecting lower respiratory tract specimens, problems distinguishing colonization from infection, poor clinical (diagnostic) sensitivity of assays, and often inadequate evaluation of new diagnostics.

This review focuses on recent advances in laboratory diagnostics that enable rapid identification of respiratory pathogens.

ANTIGEN DETECTION

Assays to detect microbial antigens in body fluids have been used for the diagnosis of respiratory infections for many years, using various formats such as immunofluorescence, enzyme-linked immunosorbent assay (ELISA), latex agglutination, coagulation, and chromatographic immunoassay. These methods are the diagnostic tools most easily applied as near-patient tests, but development is reliant on the identification of suitable antigens that are present in detectable quantities in clinical specimens. To date, commercial assays have been developed only for a limited range of pathogens. The most widely available assays have focused on the detection of selected bacterial pathogens in urine and the detection of viruses in respiratory specimens.

Among bacterial respiratory pathogens, assays for *Streptococcus pneumoniae* and *Legionella pneumophila* are the most developed. A newer generation immunochromatographic test that detects the C-polysaccharide cell wall antigen in urine (NOW) has been an important advance in the diagnosis of pneumococcal disease. This test has a sensitivity of 70% to 80% and a specificity of greater than 90% compared with conventional diagnostic methods for detection of pneumococcal pneumonia in adults. Unfortunately, the NOW test cannot be used reliably in children as it also detects pneumococcal carriage. Alternative pneumococcal antigens for diagnostic purposes, such as pneumolysin, have shown promising results, although none has been demonstrated to perform better than existing commercial C-polysaccharide antigen assays. The combination of a pneumolysin-specific antigen detection ELISA together with the NOW test may result in a better diagnostic yield because of the higher specificity of the pneumolysin detection ELISA.

Detection of soluble *Legionella* antigen in urine is an established and valuable tool for the diagnosis of Legionnaires’ disease, although current commercial assays can only reliably detect infection caused by *Legionella pneumophila* serogroup 1. Some assays have been intended to detect other legionellae, although the performance is not as good as for *L pneumophila* serogroup 1.

Detection of respiratory viral antigens in respiratory secretions has become an important diagnostic tool. Antigen detection using immunofluorescent techniques were pioneered in the 1970s, and commercial reagents are now widely used for the detection of influenza viruses, respiratory syncytial virus (RSV), parainfluenza viruses, adenoviruses, and human metapneumovirus. These assays require technical expertise and have the advantage of allowing direct evaluation of specimen quality. More
recently, commercial rapid diagnostic tests (RDTs) have become widely used for the
detection of influenza or RSV directly in respiratory specimens. These diagnostic test
kits, produced as dipsticks, cassettes, or cards, contain internal controls, and a posi-
tive result is signaled by a color change. Results are produced by these tests within
5 to 40 minutes.

The sensitivity of rapid tests for the detection of seasonal influenza in clinical spec-
imens ranges from 10% to 96%, and varies with virus type or subtype, timing of
specimen collection, specimen type, patient age, and the test comparator. With
the emergence of the pandemic influenza A (H1N1) 2009 virus, RDTs have been widely
used for patient triaging, although there are limited data available on their clinical
accuracy. The sensitivity of these assays for detecting this new strain is 10% to
69% compared with real-time PCR. Specificity of RDTs for seasonal influenza
is 90% to 100% according to the available data for H1N1 2009. Commercial RSV
RDTs have sensitivities of 71% to 95% and specificities of 80% to 100% compared
with culture. Poorer performance has been observed in adults, which may be
related to the decreased viral titer in adults compared with children.

To correctly interpret results of RDTs, the prevalence of influenza or RSV disease in
a community must be considered. During peak disease activity, positive predictive
values are highest, but false-negative results more likely. The opposite is true during
times of low disease activity. When the disease prevalence is low or unknown,
RDT results become difficult to interpret and of limited use.

NUCLEIC ACID AMPLIFICATION TESTS

The use of nucleic acid amplification tests (NAATs) has transformed our understanding
of respiratory infections, demonstrating the relevance of new agents such as human
metapneumovirus, and providing new insights into previously recognized ones such
as rhinoviruses. The progressive commercialization and clinical application of these
methods is placing them at the forefront of respiratory diagnostics.

NAATs possess several advantages over more traditional techniques for the detec-
tion of respiratory pathogens. These tests have improved sensitivity for detecting
organisms that are fastidious, no longer viable, or present in small amounts. NAATs
can provide rapid genetic information regarding sequence evolution, geographic
variation, or the presence of virulence factors or antibiotic resistance. Their rapid turn-
around times allow them a more prominent role in patient management, and the ability
of NAATs to test for multiple pathogens simultaneously has aided in the diagnosis of
nonspecific respiratory syndromes, such as in outbreak settings. Within the labora-
tory, NAATs offer enhanced opportunities for automation, and have a lower safety
risk than culture for the detection of highly virulent pathogens.

Among the NAATs, the PCR is the most common and thoroughly evaluated
method. The PCR formats most relevant for respiratory diagnostics can be clas-
sified into conventional, real-time, and multiplex platforms, with various amplicon
detection methods such as gel analysis, ELISA, DNA hybridization, or the use of fluo-
rescent dyes or chemical tags. Real-time PCR has several features that place it at an
advantage. First, the two steps of amplification and detection are combined in one
reaction, increasing the speed and efficiency of testing and reducing the risks of oper-
ator error and cross-contamination. Real-time PCR also allows for the possibility of
quantifying the amount of starting nucleic acid material.

Multiplex PCR systems, in which multiple PCR targets are sought after simulta-
aneously in one reaction, have gained wider acceptance, particularly among commer-
cial assays. These systems have the advantage of increasing the number of
pathogens tested for, without increasing the required amount of operator time or specimen material. Multiplex assays have broadened the scope of respiratory surveillance studies, and have also led to the increasing recognition of dual or triple infections in the same individual. As noted in Table 1, these assays can be differentiated by either their amplification or detection steps. In the amplification step, all multiplex platforms must balance the competing optimal PCR conditions for each individual target, and must overcome problems of competition and inhibition among the various primers and probes. Each platform uses a unique method to address these issues, such as nested primer combinations, complex primer structures, and nontraditional nucleotides. These assays are even more varied in their detection stages, where the common task is to differentially detect and report distinct populations of amplified targets. Several platforms involve solid-phase arrays, such as polystyrene microbead suspensions that use fluorescent dyes to differentiate targets, or the microchip formats that identify targets by binding to a specific physical location. The former has been developed into platforms detecting 17 to 20 targets, whereas the latter can identify between a few dozen to thousands of targets. The increased breadth of targets afforded by microarrays, however, comes at the expense of decreased sensitivity. Multiplex PCR products can also be distinguished by their size, using resolution techniques such as agarose gel electrophoresis to differentiate by weight, and capillary-based auto-sequencers that identify targets by length and sequence. Mass spectrometry can also be used for identification, either by the attachment of high molecular weight tags to primers or by the analysis of specific nucleotide base ratios that can be resolved by molecular weight.

Regardless of the platform, all PCR assays require good primer design taking into consideration gene target, gene number, mobility of genes between species, stability of gene, and the presence of mutations. Bacteria have large genomes with many genes for a fully functional organism, including their own genes for replication and enzyme product. Owing to the large genome size there are many targets available for specific detection of a bacterial species. Housekeeping genes, those genes that are essential for the survival of the organism, are desirable gene targets because they have conserved regions and hypervariable regions (eg, the 16S rRNA gene). Genes found in multicopies will also increase the sensitivity of PCR assays. The choices of viral pathogen gene targets are limited because of the limited size of the viral genome. Genes that are highly conserved are desirable targets for PCR because they allow the detection of many strains. Other genes that process areas of nucleotide hypervariability caused by genetic mutation should be avoided because changes over primer and probe sites can cause poor PCR efficiency and the potential for false-negative results. Table 2 lists some of the more common respiratory pathogen target genes.

The published literature on NAATs can be difficult to interpret, because study designs vary and rarely involve head-to-head comparisons among the different assays. Calculation of clinical sensitivity and specificity is complicated because NAATs often are more sensitive than the reference culture-based standards. Comparisons of study results are also problematic because of the use of different specimen types that may have differential yields for pathogens. Finally, several NAAT platforms require investment in specialized equipment, the cost of which can only be recovered through high-volume testing. Therefore, few NAAT assays for respiratory diagnosis are licensed for clinical use, and their daily use in clinical practice remains uncommon. To promote widespread adoption in the future, developers of NAAT diagnostics will need to standardize evaluation methods, particularly in comparison with reference
techniques, reduce complexity and cost, and better demonstrate their utility in the clinical environment.

**NAATs for Specific Respiratory Pathogens**

Although NAATs have been developed for all important respiratory pathogens, the clinical application of these tests varies. Perhaps the area that NAATs have had the greatest impact is for the diagnosis of infections caused by respiratory viruses.\(^{29,49,50}\) For most, if not all, respiratory viruses, detection of viral nucleic acid is the most sensitive diagnostic approach, and current “gold standards” (namely, culture and direct immunofluorescence) will be eventually replaced by NAATs.\(^{50}\) PCR has become the diagnostic test of choice for some respiratory viral infections (e.g., for influenza during the current influenza H1N1 pandemic), and is a useful epidemiologic tool for characterizing the role of viruses in various disease states.\(^{51}\) NAATs can provide results rapidly and are able to detect many viral pathogens that are unable to be readily detected by culture. Perhaps more so than for other respiratory pathogens, considerable effort has been directed toward the development of multiplex assays to enable the simultaneous detection of multiple viral pathogens. Given the increasingly large number of respiratory viruses, this can be a challenging task.

The need for improved diagnostic tools for pneumococcal disease has lead to the evaluation of several NAATs. For pneumonia, PCR has a sensitivity for detecting *S pneumoniae* in blood samples ranging from 29% to 100%,\(^{27}\) with a tendency for higher sensitivity in children than adults. The finding of positive pneumococcal PCR results from asymptomatic control subjects complicates interpretation.\(^{52–54}\) When testing sputum samples from adults with pneumonia, PCR positivity has ranged from 68% to 100%,\(^{27}\) although it is unclear how often this reflects upper respiratory tract colonization rather than infection.\(^{55}\) Further refinement of PCR assays, including the use of multiple targets, has increased the specificity,\(^{56}\) with lytA assays potentially offering advantages over other assays.\(^{57,58}\) Quantification of *S pneumoniae* DNA load may provide additional diagnostic and prognostic information. Quantitative PCR may help distinguish colonization from infection, with a higher bacterial burden in pneumococcal disease than in a carrier state.\(^{59}\) High pneumococcal DNA loads in blood have been recently shown to be associated with severe disease in various settings.\(^{60–62}\)

NAATs have improved the ability of diagnostic laboratories to detect respiratory pathogens that are difficult to culture, such as *Mycoplasma pneumoniae*, *Legionella* species, and *Chlamydophila pneumoniae*. An extensive evaluation of 13 antibody detection assays using PCR as the comparator standard concluded that few commercial serologic assays for detection of *M pneumoniae* performed with sufficient sensitivity and specificity, and highlighted the increasing importance of NAATs.\(^{63}\) Indeed PCR is considered by many to be the method of choice for detection of *M pneumoniae* infection.\(^{64}\) Both upper and lower respiratory tract samples are suitable for testing for *M pneumoniae* by PCR, although throat swabs and nasopharyngeal samples may be preferred because of high sensitivity, high specificity, and convenience. In practice, PCR has been successfully used to rapidly diagnose mycoplasma pneumonia during outbreaks, and was particularly useful in children, immunocompromised patients, and in early-stage disease.\(^{65,66}\)

Legionnaires’ disease can be difficult to diagnose, and NAATs have proven a useful adjunct to culture and antigen detection.\(^9\) PCR has repeatedly been shown to have sensitivity equal to or greater than culture when testing lower respiratory specimens.\(^{67–73}\) *Legionella* DNA can also be detected in nonrespiratory specimens, such as urine, serum, and peripheral leukocytes,\(^9\) although testing these specimen types is not well established.
| Platform                | Targets Included                                                                 | Assays Available                      | Analytical Performance                                                                 | Clinical Performance                                                                 | Development Timeframe | Flexibility                                      | Turnaround Time | Specimen Requirements | Quantitation | Licensing Status       |
|------------------------|----------------------------------------------------------------------------------|----------------------------------------|----------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|----------------------|--------------------------------------------------|-----------------|------------------------|--------------|------------------------|
| Real-time PCR (rtPCR)  | Variable; maximum of 4–5 targets per assay, can run parallel reactions, limited by sample volume | Various in-house protocols             | Likely highest sensitivity, eg, 1 pfu/mL, 10 copies/reaction                           | Good; singleplex rtPCR is often the gold standard molecular diagnostic               | Depends on the originating laboratory | Multipleplex must be optimized for each additional target, limited to 5 total targets | Half-day        | None                   | Yes          | Some approved for in vitro diagnosis (IVD), others research use only (RUO) |
| Microbead array        | 17–20 viral or bacterial targets in each assay                                    | Qiagen (Resplex I [bacterial] and II [viral]), Luminex, and Eragen Biosciences     | Varies by kit and pathogen; limits of detection reported at 60 copies/reaction, or 0.1–100 TCID<sub>50</sub>/mL | Sensitivity 72%–100% compared with culture plus rtPCR; varies by target, reduced by dual infections | All are commercially available | Multiplex must be optimized for each additional target; up to 30 can be detected at once; commercial kits may be slow to modify | 6–8 h          | No                     | IVD (Luminex); RUO (Qiagen, Eragen) |
| Mass spectrometry      | All main respiratory viruses and bacteria                                         | MassTag, IBIS                         | MassTag: 500–1000 copies/reaction, 1 TCID<sub>50</sub>/mL; IBIS: 50 copies/well (basically singleplex) | Not rigorously evaluated                                                               | Unknown               | Requires optimization of multiplex; detection methods unrestricted | Half to 1 day   | No                     | RUO          |                        |
| Commercial multiplex | All main respiratory viruses and bacteria | Seegene (Seeplex) | 10–100 copies/reaction | 96%–100% concordance with DFA and sequencing | Commercially available | Multiplex apparently tolerant of additional targets; detection method determined separately | 6–8 h | No sputum | No | IVD in Europe and Canada, RUO in USA |
|----------------------|----------------------------------------|-----------------|------------------------|-----------------------------------------------|----------------------|--------------------------------------------------------------------------------|-------|-------|-----|----------------------------------|
| Microarray           | Several thousand viruses, bacteria, fungi, and parasites | Greenechip, Virochip, Autogenomics | 10–10,000 copies/reaction | No data | Unknown | Not generally customizable | No data | No data | No | RUO |
| 16S rRNA             | All bacteria and mycobacteria | Viruses | Can detect low abundance organisms | For bacteremia, 87% sensitivity, 86% specificity vs blood culture | Assay for respective pathogens is in development | Not applicable | PCR 3–4 h, analysis time 3–4 h | ND | No | RUO |
| Ultrahigh throughput screening | All microbes | None | Limit of detection 5500 copies/mL | No data | No data | Not applicable | ND | ND; likely none | No | RUO |

**Abbreviations:** DFA, direct fluorescence assay; ND, not determined; TCID_{50}, tissue culture infective dose needed to produce 50% change.
| Organism                     | Genome | Size (nt) | Target                        | Function               |
|------------------------------|--------|-----------|-------------------------------|------------------------|
| *Streptococcus pneumoniae*   | dsDNA  | ~2,040,000| *ply* *lytA* *psaA* 16S rRNA  | Detection              |
| *Haemophilus influenzae*     | dsDNA  | ~1,830,138| 16S rRNA BexA                 | Detection              |
| *Moraxella catarrhalis*      | dsDNA  | ~1,940,000| 16S rRNA                      | Detection              |
| *Legionella*                 | dsDNA  | ~3,576,470| 16S rRNA mip                  | Detection              |
| *Mycoplasma pneumoniae*      | dsDNA  | ~816,394  | 16S rRNA P1 adhesion gene CARDS toxin | Detection              |
| *Chlamydophila pneumoniae*   | dsDNA  | ~1,225,935| omp-2 gene                    | Detection              |
| *Bordetella pertussis*       | dsDNA  | ~4,086,189| IS481 adenylate cyclase toxin (ACT) gene | Detection              |
| *Mycobacterium tuberculosis* | dsDNA  | ~4,411,532| IS6110 16S rRNA               | Detection              |
| *Pneumocystis jiroveci*      | dsDNA  | ~8,400,000| 18S rRNA, mitochondrial (mt) rRNA 5S rRNA | Detection              |
| Adenovirus                   | dsDNA  | ~36,000   | Hexon gene Fiber gene         | Detection and genotyping|
| Enterovirus                  | ssRNA (+)| ~7500    | 5'UTR VP1,2                   | Detection              |

Murdoch et al.
| Virus                  | Type | Molecular Weight | Gene Products                                      | Detection/Genotyping |
|------------------------|------|------------------|---------------------------------------------------|----------------------|
| Rhinovirus             | ssRNA (+) | ~7500           | 5’UTR VP1,2                                       | Genotyping           |
| Coronavirus 229E, OC43, SARS, NL63, HKU-1 | ssRNA (+) | ~30,000         | Polymerase gene Nucleocapsid gene ORF1            | Detection            |
| Influenza A            | ssRNA (-) | ~12,000          | Matrix protein gene                               | Detection            |
| Influenza B            | ssRNA (-) | ~12,000          | Hemagglutinin gene                                | Detection            |
| Parainfluenza virus 1, 2, 3, and 4 | ssRNA (-) | ~15,600         | Hemagglutinin gene                               | Detection            |
| RSV                    | ssRNA (-) | ~15,600          | Fusion protein (F) Nucleoprotein (N)              | Detection            |
| hMPV                   | ssRNA (-) | ~14,000          | Fusion protein Nucleoprotein Large polymerase (L) protein gene | Detection            |
| Bovine virus           | ssDNA | ~5,500           | Viral protein (VP1) Nonstructural protein (NP1)   | Detection            |

**Abbreviations:** ORF, open reading frame; UTR, untranslated region.
PCR has been extensively evaluated for the rapid diagnosis of *C pneumoniae* infection using various assays.74 A standardized approach to *C pneumoniae* diagnostic testing was published in 2001 by the US Centers for Disease Control and Prevention and the Canadian Laboratory Center for Disease Control.75 However, there are still few evaluations that have extensively used clinical samples, and the great variety in the methods used makes it difficult to make firm conclusions about performance. To further complicate matters, significant interlaboratory discordance of detection rates have been recorded for some assays.76,77

The diagnostic yield from PCR is consistently greater than for culture when testing nasopharyngeal samples for *Bordetella pertussis*.27 PCR remains positive for a longer period after the onset of symptoms and thus is useful for individuals who present late in their illness.78 In the investigation of a pertussis outbreak, the combination of PCR and culture for samples obtained 2 weeks or less after illness onset and PCR alone for samples obtained more than 2 weeks after illness onset proved to be the most diagnostically useful.79

PCR has greater sensitivity than cytologic methods for the detection of *Pneumocystis jiroveci*, although it has been difficult to interpret the common finding of PCR-positive samples that are negative by standard methods.27 The latter may reflect *P jiroveci* colonization of uncertain clinical significance. The performance of PCR has been shown to vary with different assays,80 although the results correlate well with clinical evidence of pneumocystis pneumonia.81

The need for improved diagnostic methods for tuberculosis has focused attention on the potential role of NAATs. Advances in this area have been relatively slow, with NAATs for mycobacteria failing to provide greater sensitivity than culture-based methods. The relatively high false-negative rate with NAATs for *Mycobacterium tuberculosis* probably reflects a combination of the paucibacillary nature of samples, presence of inhibitors in samples, and suboptimal DNA extraction methods. The situation is changing, with new developments in rapid diagnosis and antibiotic susceptibility testing.82 For direct detection of *M tuberculosis* in respiratory samples, all commercial assays have high specificity (>98%), but variable sensitivities: 90% to 100% for smear-positive samples and 33% to 100% for smear-negative samples.27 Consequently, it is recommended that use of these tests is restricted to only smear-positive samples. Evaluations of PCR for the diagnosis of tuberculosis in high-prevalence populations have been promising.83–86 Alternative strategies under development to diagnose tuberculosis by molecular tools include detection of mycobacterial DNA in urine87,88 and direct detection in respiratory specimens by microarray.89

**New Pathogen Discovery**

The NAATs discussed herein target known pathogens. When NAATs fail to identify an agent, additional tools are needed to pursue an etiologic diagnosis as might be indicated in an outbreak setting. These additional methods include microarrays and high-throughput sequencing.42,90,91 Proteomics also has a potential for being developed as a tool for pathogen discovery.92

**BREATH ANALYSIS**

Breath analysis is an exciting new area with enormous diagnostic potential.93–95 Alveolar breath contains many biomarkers derived from the blood by passive diffusion across the alveolar membrane,93 and also contains direct markers of lung injury.96–98 Breath testing is noninvasive, easily repeatable, and requires minimal specimen
workup. Various testing methodologies and sample types have been used in breath
research, usually involving the measurement of exhaled permanent gases, detection
of volatile organic compounds, or analysis of exhaled breath condensate.

The use of breath analysis for the investigation of respiratory infections has not yet
been extensively evaluated. Electronic nose devices detect volatile molecules as they
interact with chemical sensor assays.\textsuperscript{99–101} Based on the reactivity of multiple sensors
to the volatile molecules, an electronic signature is generated. Testing of exhaled
breath by a portable electronic nose has been used to diagnose pneumonia in
mechanically ventilated patients.\textsuperscript{102–104} The clinical impact of this device needs further
evaluation, but it could be used as a trigger for further diagnostic studies in pneumonia
such as bronchoscopy.

Microorganisms produce volatile metabolites that may be used as biomarkers.\textsuperscript{105} Detection of these biomarkers in breath samples by gas chromatography/mass spec-
troscopy or similar methods may provide an etiologic diagnosis of respiratory tract
infection. Ideally, specific biomarkers need to be identified, and it may be difficult to
discover unique markers for each pathogen produced in sufficient quantities to enable
detection. Potential biomarkers have been reported for some respiratory pathogens,
such as \textit{Aspergillus fumigatus}\textsuperscript{106,107} and \textit{M tuberculosis},\textsuperscript{108,109} but it is still uncertain
whether they will prove to be useful as clinical diagnostic tools.

**FUTURE PROSPECTS**

Diagnostic tests for respiratory infections will continue to evolve and become more
user-friendly. Antigen-detection assays in immunochromatographic or similar formats
are rapid, simple to perform, and are most easily developed as near-patient tests.
These methods are among the most attractive diagnostic tools, but further develop-
ment is reliant on the discovery of suitable antigens that can be reliably detected in
readily obtained specimens. NAATs have now been developed to a stage where multi-
plex assays that detect the common respiratory pathogens are commercially avail-
able, although not all have been rigorously evaluated in clinical settings. Further
improvements in design and performance are expected, and an emphasis should
be placed on clarifying the clinical usefulness of NAATs, developing standardized
methods, producing even more user-friendly platforms, and exploring the role of
quantitative assays. New approaches for respiratory pathogen detection are desper-
ately needed. Breath analysis is an exciting new area with enormous potential, and it
will be interesting to follow progress in this area over the next few years.

**REFERENCES**

1. Peiris JSM, Yuen KY, Osterhaus A, et al. Current concepts: the severe acute
respiratory syndrome. N Engl J Med 2003;349:2431–41.
2. WHO Collaborating Center. CDC protocol of real-time RT-PCR for influenza
A (H1N1), 2009. Available at: http://www.who.int/csr/resources/publications/
swineflu/CDCRealtimeRTPCR_SwineH1Assay-2009_20090430.pdf. Accessed
May 22, 2010.
3. Murdoch DR, O’Brien KL, Scott JAG, et al. Breathing new life into pneumonia
diagnostics. J Clin Microbiol 2009;47:3405–8.
4. Werno AM, Murdoch DR. Laboratory diagnosis of invasive pneumococcal
disease. Clin Infect Dis 2008;46:926–32.
5. Dowell SF, Garman RL, Liu G, et al. Evaluation of Binax NOW, an assay for the
detection of pneumococcal antigen in urine samples, performed among pedi-
atric patients. Clin Infect Dis 2001;32:824–5.
6. Cima-Cabal MD, Méndez FJ, Vázquez F, et al. Immunodetection of pneumolysin in human urine by ELISA. J Microbiol Methods 2003;54:47–55.
7. García-Suárez MDM, Cima-Cabal MD, Villaverde R, et al. Performance of a pneumolysin ELISA assay for the diagnosis of pneumococcal infections. J Clin Microbiol 2007;45:3549–54.
8. Rajalakshmi B, Kanungo R, Srinivasan S, et al. Pneumolysin in urine: a rapid antigen detection method to diagnose pneumococcal pneumonia in children. Ind J Med Microbiol 2002;20:183–6.
9. Murdoch DR. Diagnosis of Legionella infection. Clin Infect Dis 2003;36:64–9.
10. Harrison T, Uldum S, Alexiou-Daniel S, et al. A multicenter evaluation of the Biotest legionella urinary antigen EIA. Clin Microbiol Infect 1998;4:359–65.
11. Abanses JC, Dowd MD, Simon SD, et al. Impact of rapid influenza testing at triage on management of febrile infants and young children. Pediatr Emerg Care 2006;22:145–9.
12. Jafri HS, Ramiolo O, Makari D, et al. Diagnostic virology practices for respiratory syncytial virus and influenza virus among children in the hospital setting: a national survey. Pediatr Infect Dis J 2007;26:956–8.
13. Jennings LC, Skopnik H, Burckhardt I, et al. Effect of rapid influenza testing on the clinical management of paediatric influenza. Influenza Other Respi Viruses 2009;3:91–8.
14. Hurt AC, Alexander R, Hibbert J, et al. Performance of six influenza rapid tests in detecting human influenza in clinical specimens. J Clin Virol 2007;39:132–5.
15. Uyeki TM. Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza. Pediatr Infect Dis J 2003;22:164–77.
16. Smit M, Beynon KA, Murdoch DR, et al. Comparison of the NOW Influenza A & B, NOW Flu A, NOW Flu B, and Directigen Flu A+B assays, and immunofluorescence with viral culture for the detection of influenza A and B viruses. Diagn Microbiol Infect Dis 2007;57:67–70.
17. World Health Organization. WHO recommendations on the use of rapid testing for influenza diagnosis. WHO, 2005; Available at: http://www.who.int/csr/disease/avian_influenza/guidelines/rapid_testing/en/index.html. Accessed May 22, 2010.
18. Chan KH, Lai ST, Poon LL, et al. Analytical sensitivity of rapid influenza antigen detection tests for swine-origin influenza virus (H1N1). J Clin Virol 2009;45:205–7.
19. Hurt AC, Baas C, Deng YM, et al. Performance of influenza rapid point-of-care tests in the detection of swine lineage A(H1N1) influenza viruses. Influenza Other Respi Viruses 2009;3:171–6.
20. Centers for Disease Control and Prevention. Evaluation of rapid influenza diagnostic tests for detection of novel influenza A (H1N1) virus—United States, 2009. MMWR Morb Mortal Wkly Rep 2009;58:826–9.
21. Faix DJ, Sherman SS, Waterman SH. Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009;361:728–9.
22. Ginocchio CC, Zhang F, Manji R, et al. Evaluation of multiple test methods for the detection of the novel 2009 influenza A (H1N1) during the New York City outbreak. J Clin Virol 2009;45:191–5.
23. Borek AP, Clemens SH, Gaskins VK, et al. Respiratory syncytial virus detection by Remel Xpect, Binax Now RSV, direct immunofluorescent staining, and tissue culture. J Clin Microbiol 2006;44:1105–7.
24. Selvarangan R, Abel D, Hamilton M. Comparison of BD Directigen EZ RSV and Binax NOW RSV tests for rapid detection of respiratory syncytial virus from
nasopharyngeal aspirates in a pediatric population. Diagn Microbiol Infect Dis 2008;62:157–61.

25. Zheng X, Quianzon S, Mu Y, et al. Comparison of two new rapid antigen detection assays for respiratory syncytial virus with another assay and shell vial culture. J Clin Virol 2004;31:130–3.

26. Casiano-Colón AE, Hulbert BB, Mayer TK, et al. Lack of sensitivity of rapid antigen tests for the diagnosis of respiratory syncytial virus infection in adults. J Clin Virol 2003;28:169–74.

27. Murdoch DR. Molecular genetic methods in the diagnosis of lower respiratory tract infections. APMIS 2004;112:713–27.

28. Barken KB, Haagensen JAJ, Toller-Nielsen T. Advances in nucleic acid-based diagnostics of bacterial infections. Clin Chim Acta 2007;384:1–11.

29. Ieven M. Currently used nucleic acid amplification tests for the detection of viruses and atypical in acute respiratory infections. J Clin Virol 2007;40:259–76.

30. Brunstein JD, Cline CL, McKinney S, et al. Evidence from multiplex molecular assays for complex multipathogen interactions in acute respiratory infections. J Clin Microbiol 2008;46:97–102.

31. Li H, McCormac MA, Estes RW, et al. Simultaneous detection and high-throughput identification of a panel of RNA viruses causing respiratory tract infections. J Clin Microbiol 2007;45:2105–9.

32. Kim SR, Ki CS, Lee NY. Rapid detection and identification of 12 respiratory viruses using a dual priming oligonucleotide system-based multiplex PCR assay. J Virol Methods 2009;156:111–6.

33. Roh KH, Kim J, Nam MH, et al. Comparison of the Seeplex reverse transcription PCR assay with the R-mix viral culture and immunofluorescence techniques for detection of eight respiratory viruses. Ann Clin Lab Sci 2008;38:41–6.

34. Lee WM, Grindle K, Pappas T, et al. High-throughput, sensitive, and accurate multiplex PCR-microsphere flow cytometry system for large-scale comprehensive detection of respiratory viruses. J Clin Microbiol 2007;45:2626–34.

35. Marshall DJ, Reisdorf E, Harms G, et al. Evaluation of a multiplexed PCR assay for detection of respiratory viral pathogens in a public health laboratory setting. J Clin Microbiol 2007;45:3875–82.

36. Nolte FS, Marshall DJ, Rasures C, et al. MultiCode-PLx system for multiplexed detection of seventeen respiratory viruses. J Clin Microbiol 2007;45:2779–86.

37. Mahony J, Chong S, Merante F, et al. Development of a respiratory virus panel test for detection of twenty human respiratory viruses by use of multiplex PCR and a fluid microbead-based assay. J Clin Microbiol 2007;45:2965–70.

38. Pabbaraju K, Tokaryk KL, Wong S, et al. Comparison of the Luminex xTAG respiratory viral panel with in-house nucleic acid amplification tests for diagnosis of respiratory virus infections. J Clin Microbiol 2008;46:3056–62.

39. Chiu CY, Urisman A, Greenhow TL, et al. Utility of DNA microarrays for detection of viruses in acute respiratory tract infections in children. J Pediatr 2008;153:76–83.

40. Quan P-L, Palacios G, Jabado OJ, et al. Detection of respiratory viruses and subtype identification of influenza A viruses by GreeneChipResp oligonucleotide microarray. J Clin Microbiol 2007;45:2359–64.

41. Raymond F, Carbonneau J, Boucher N, et al. Comparison of automated microarray detection with real-time PCR assays for detection of respiratory viruses in specimens obtained from children. J Clin Microbiol 2009;47:743–50.

42. Quan P-L, Briese T, Palacios G, et al. Rapid sequence-based diagnosis of viral infection. Antiviral Res 2008;79:1–5.
43. Briese T, Palacios G, Kokoris M, et al. Diagnostic system for rapid and sensitive
differential detection of pathogens. Emerg Infect Dis 2005;11:310–3.
44. Dominguez SR, Briese T, Palacios G, et al. Multiplex MassTag-PCR for respira-
tory pathogens in pediatric nasopharyngeal washes negative by conventional
diagnostic testing shows a high prevalence of viruses belonging to a newly
recognized rhinovirus clade. J Clin Virol 2008;43:219–22.
45. Lamson D, Renwick N, Kapoor V, et al. MassTag polymerase-chain-reaction
detection of respiratory pathogens, including a new rhinovirus genotype, that
caused influenza-like illness in New York State during 2004-2005. J Infect Dis
2006;194:1398–402.
46. Renwick N, Schweiger B, Kapoor V, et al. A recently identified rhinovirus geno-
type is associated with severe respiratory-tract infection in children in Germany.
J Infect Dis 2007;196:1754–60.
47. Ecker DJ, Sampath R, Massire C, et al. Ibis T5000: a universal biosensor
approach for microbiology. Nature Rev Microbiol 2008;6:553–8.
48. Loens K, Van Heirstraeten L, Malhotra-Kumar S, et al. Optimal sampling sites
and methods for detection of pathogens possibly causing community-
acquired lower respiratory tract infections. J Clin Microbiol 2009;47:21–31.
49. Fox JD. Nucleic acid amplification tests for detection or respiratory viruses.
J Clin Virol 2007;40(Suppl 1):S15–23.
50. Mahony JB. Detection of respiratory viruses by molecular methods. Clin Micro-
biol Rev 2008;21:716–47.
51. Jennings LC, Anderson TP, Beynon KA, et al. Incidence and characteristics of
viral community-acquired pneumonia in adults. Thorax 2008;63:42–8.
52. Dagan R, Shriker O, Hazan I, et al. Prospective study to determine clinical rele-
vance of detection of pneumococcal DNA in sera of children by PCR. J Clin
Microbiol 1998;36:669–73.
53. Rudolph KM, Parkinson AJ, Black CM, et al. Evaluation of polymerase chain
reaction for diagnosis of pneumococcal pneumonia. J Clin Microbiol 1993;31:
2661–6.
54. Salo P, Ortvquist A, Leinonen M. Diagnosis of bacteremic pneumococcal pneu-
monia by amplification of pneumolysin gene fragment in serum. J Infect Dis
1995;171:479–82.
55. Murdoch DR, Anderson TP, Beynon KA, et al. Evaluation of a PCR assay for
detection of Streptococcus pneumoniae in respiratory and nonrespiratory
samples from adults with community-acquired pneumonia. J Clin Microbiol
2003;41:63–6.
56. Sheppard CL, Harrison TG, Morris R, et al. Autolysin-targeting LightCycler
assay including internal process control for detection of Streptococcus pneumo-
niae DNA in clinical samples. J Med Microbiol 2004;53:189–95.
57. Carvalho MGS, Tondella ML, McCaustland K, et al. Evaluation and improvement
of real-time PCR assays targeting lytA, ply, and psaA genes for detection of
pneumococcal DNA. J Clin Microbiol 2007;45:2460–6.
58. Smith MD, Sheppard CL, Hogan A, et al. Diagnosis of Streptococcus pneumo-
niae infections in adults with bacteremia and community-acquired pneumonia:
clinical comparison of pneumococcal PCR and urinary antigen detection.
J Clin Microbiol 2009;47:1046–9.
59. Kais M, Spindler C, Kalin M, et al. Quantitative detection of Streptococcus pneu-
niae, Haemophilus influenzae, and Moraxella catarrhalis in lower respira-
tory tract samples by real-time PCR. Diagn Microbiol Infect Dis 2006;55:
169–78.
60. Carrol ED, Guiver M, Nkhoma S, et al. High pneumococcal DNA loads are associated with mortality in Malawian children with invasive pneumococcal disease. Pediatr Infect Dis J 2007;26:416–22.
61. Peters RPH, de Boer RF, Schuurman T, et al. *Streptococcus pneumoniae* DNA load in blood as marker of infection in patients with community-acquired pneumonia. J Clin Microbiol 2009;47:3308–12.
62. Rello J, Lisboa T, Lujan M, et al. Severity of pneumococcal pneumonia associated with genomic bacterial load. Chest 2009;136:832–40.
63. Beersma MFC, Dirven K, van Dam AP, et al. Evaluation of 12 commercial tests and the complement fixation test for *Mycoplasma pneumoniae*-specific immunoglobulin G (IgG) and IgM antibodies, with PCR use as the “gold standard”. J Clin Microbiol 2005;43:2277–85.
64. Daxboeck F, Krause R, Wenisch C. Laboratory diagnosis of *Mycoplasma pneumoniae* infection. Clin Microbiol Infect 2003;9:263–73.
65. Kim NH, Lee JA, Eun BW, et al. Comparison of polymerase chain reaction and the indirect particle agglutination antibody test for the diagnosis of *Mycoplasma pneumoniae* pneumonia in children during two outbreaks. Pediatr Infect Dis J 2007;26:897–903.
66. Liu F-C, Chen P-Y, Huang F-L, et al. Rapid diagnosis of *Mycoplasma pneumoniae* infection in children by polymerase chain reaction. J Microbiol Immunol Infect 2007;40:507–12.
67. Cloud JL, Carroll KC, Pixton P, et al. Detection of *Legionella* species in respiratory specimens using PCR with sequencing confirmation. J Clin Microbiol 2000;38:1709–12.
68. Jaulhac B, Nowicki M, Bornstein N, et al. Detection of *Legionella* spp. in bronchoalveolar lavage fluids by DNA amplification. J Clin Microbiol 1992;30:920–4.
69. Jonas D, Rosenbaum A, Weyrich S, et al. Enzyme-linked immunoassay for detection of PCR-amplified DNA of legionellae in bronchoalveolar fluid. J Clin Microbiol 1995;33:1247–52.
70. Kessler HH, Reinthaler FF, Pschaid A, et al. Rapid detection of *Legionella* species in bronchoalveolar lavage fluids with the EnviroAmp *Legionella* PCR amplification and detection kit. J Clin Microbiol 1993;31:3325–8.
71. Lisby G, Dessau R. Construction of a DNA amplification assay for detection of *Legionella* species in clinical samples. Eur J Clin Microbiol Infect Dis 1994;13:225–31.
72. Matsiota-Bernard P, Pitsouni E, Legakis N, et al. Evaluation of commercial amplification kit for detection of *Legionella pneumophila* in clinical specimens. J Clin Microbiol 1994;32:1503–5.
73. Weir SC, Fischer SH, Stock F, et al. Detection of *Legionella* by PCR in respiratory specimens using a commercially available kit. Am J Clin Pathol 1998;110:295–300.
74. Kumar S, Hammerschlag MR. Acute respiratory infection due to *Chlamydia pneumoniae*: current status of diagnostic methods. Clin Infect Dis 2007;44:568–76.
75. Dowell SF, Peeling RW, Boman J, et al. Standardizing *Chlamydia pneumoniae* assays: recommendations from the Centers for Diseases Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001;33:492–503.
76. Apfalter P, Assadian O, Blasi F, et al. Reliability of nested PCR for detection of *Chlamydia pneumoniae* DNA in atheromas: results from a multicenter study applying standardized protocols. J Clin Microbiol 2002;40:4428–34.
77. Apfalter P, Blasi F, Boman J, et al. Multicenter comparison trial of DNA extraction methods and PCR assays for detection of *Chlamydia pneumoniae* in endarterectomy specimens. J Clin Microbiol 2001;39:519–24.

78. Muller FM, Hoppe JE, Wrasing von Kohig CH. Laboratory diagnosis of pertussis: state of the art in 1997. J Clin Microbiol 1997;35:2435–43.

79. Sotir MJ, Cappozzo DL, Warshauer DM, et al. Evaluation of polymerase chain reaction and culture for diagnosis of pertussis in the control of a county-wide outbreak focused among adolescents and adults. Clin Infect Dis 2007;44:1216–9.

80. Robberts FJL, Liebowitz LD, Chalkley LJ. Polymerase chain reaction detection of *Pneumocystis jiroveci*: evaluation of 9 assays. Diagn Microbiol Infect Dis 2007;58:385–92.

81. Azoulay E, Bergeron A, Chevret S, et al. Polymerase chain reaction for diagnosing pneumocystis pneumonia in non-HIV immuno compromised patients with pulmonary infiltrates. Chest 2009;135:655–61.

82. Balasingham SV, Davidsen T, Szpinda I, et al. Molecular diagnostics in tuberculosis: basis and implications for therapy. Mol Diagn Ther 2009;13:137–51.

83. Kibiki GS, Mulder B, van der Ven AJ, et al. Laboratory diagnosis of pulmonary tuberculosis in TB and HIV endemic settings and the contribution of real time PCR for *M. tuberculosis* in bronchoalveolar lavage fluid. Trop Med Int Health 2007;12:1210–7.

84. Kivihiya-Ndugga L, van Cleeff M, Juma E, et al. Comparison of PCR with the routine procedure for diagnosis of tuberculosis in a population with high prevalences of tuberculosis and human immunodeficiency virus. J Clin Microbiol 2004;42:1012–5.

85. Ani A, Okpe S, Akambi M, et al. Comparison of a DNA based PCR method with conventional methods for the detection of *M. tuberculosis* in Jos, Nigeria. J Infect Dev Ctries 2009;3:470–5.

86. Ben Kahla I, Ben Selma W, Marzouk M, et al. Evaluation of a simplified IS6110 PCR for the rapid diagnosis of *Mycobacterium tuberculosis* in an area with high tuberculosis incidence. Pathol Biol. DOI:10.1016/j.pathbio.2009.04.001.

87. Green C, Huggett JF, Talbot E, et al. Rapid diagnosis of tuberculosis through the detection of mycobacterial DNA in urine by nucleic acid amplification methods. Lancet Infect Dis 2009;9:505–11.

88. Gopinath K, Singh S. Urine as an adjunct specimen for the diagnosis of active pulmonary tuberculosis. Int J Infect Dis 2009;13:374–9.

89. Chang HJ, Huang MY, Yeh CS, et al. Rapid diagnosis of tuberculosis directly from clinical specimens by gene chip. Clin Microbiol Infect. DOI:10.1111/j.1469-0691.2009.03045.x.

90. Lipkin WI, Gustavo P, Thomas B. Diagnostics and discovery in viral hemorrhagic fevers. Ann N Y Acad Sci 2009;1171(S1):E6–11.

91. Palacios G, Druce J, Du L, et al. A new arenavirus in a cluster of fatal transplant-associated diseases. N Engl J Med 2008;358:991–8.

92. Ye Y, Mar E-C, Tong S, et al. Application of proteomics methods for pathogen discovery. J Virol Methods 2010;163:87–95.

93. Cao W, Duan Y. Breath analysis: potential for clinical diagnosis and exposure assessment. Clin Chem 2006;52:800–11.

94. Corradi M, Mutti A. Exhaled breath analysis: from occupational to respiratory medicine. Acta Biomed 2005;76(Suppl 2):20–9.
95. Risby TH, Solga SF. Current status of clinical breath analysis. Appl Phys B 2006; 85:421–6.

96. Majewska E, Kasielski M, Luczynski R, et al. Elevated exhalation of hydrogen peroxide and thiobarbituric acid reactive substances in patients with community acquired pneumonia. Respir Med 2004;98:669–76.

97. Romero PV, Rodríguez B, Martínez S, et al. Analysis of oxidative stress in exhaled breath condensate from patients with severe pulmonary infections. Arch Bronconeumol 2006;42:113–9.

98. Sack U, Scheibe R, Wötzel M, et al. Multiplex analysis of cytokines in exhaled breath condensate. Cytometry A 2006;69:169–72.

99. Nagle HT, Schiffman SS, Gutierrez-Osuna R. The how and why of electronic noses. IEEE Spectrum 1998;35:22–34.

100. Pearce TC. Computational parallels between the biological olfactory pathway and its analogue ‘The Electronic Nose’: Part I. Biological olfaction. Biosystems 1997;41:43–67.

101. Thaler ER, Hanson CW. Medical applications of electronic nose technology. Expert Rev Med Devices 2005;2:559–66.

102. Hanson CW, Thaler ER. Electronic nose prediction of a clinical pneumonia score: biosensors and microbes. Anesthesiology 2005;102:63–8.

103. Hockstein NG, Thaler ER, Lin Y, et al. Correlation of pneumonia score with electronic nose signature: a prospective study. Ann Otol Rhinol Laryngol 2005;114:504–8.

104. Hockstein NG, Thaler ER, Torigian D, et al. Diagnosis of pneumonia with an electronic nose: correlation of vapor signature with chest computed tomography scan findings. Laryngoscope 2004;114:1701–5.

105. Allardyce RA, Langford VS, Hill AL, et al. Detection of volatile metabolites produced by bacterial growth in blood culture media by selected ion flow tube mass spectrometry (SIFT-MS). J Microbiol Meth 2006;65:361–5.

106. Syhre M, Scotter JM, Chambers ST. Investigation into the production of 2-pentylfuran by Aspergillus fumigatus and other respiratory pathogens in vitro and human breath samples. Med Mycol 2008;46:209–15.

107. Chambers ST, Syhre M, Murdoch DR, et al. Detection of 2-pentylfuran in the breath of patients with Aspergillus fumigatus. Med Mycol 2009;47:468–76.

108. Syhre M, Chambers ST. The scent of Mycobacterium tuberculosis. Tuberculosis 2008;88:317–23.

109. Syhre M, Manning L, Phuanukoonnnon S, et al. The scent of Mycobacterium tuberculosis—Part II: breath. Tuberculosis 2009;89:263–6.